The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): study protocol for a randomized controlled trial

Sofia Straudi, Fabio Manfredini, Nicola Lamberti, Paolo Zamboni, Francesco Bernardi, Giovanna Marchetti, Paolo Pinton, Massimo Bonora, Paola Secchiero, Veronica Tisato, Stefano Volpato, Nino Basaglia, Sofia Straudi, Fabio Manfredini, Nicola Lamberti, Paolo Zamboni, Francesco Bernardi, Giovanna Marchetti, Paolo Pinton, Massimo Bonora, Paola Secchiero, Veronica Tisato, Stefano Volpato, Nino Basaglia

Abstract

Background: Gait and mobility impairments affect the quality of life (QoL) of patients with progressive multiple sclerosis (MS). Robot-assisted gait training (RAGT) is an effective rehabilitative treatment but evidence of its superiority compared to other options is lacking. Furthermore, the response to rehabilitation is multidimensional, person-specific and possibly involves functional reorganization processes. The aims of this study are: (1) to test the effectiveness on gait speed, mobility, balance, fatigue and QoL of RAGT compared to conventional therapy (CT) in progressive MS and (2) to explore changes of clinical and circulating biomarkers of neural plasticity.

Methods: This will be a parallel-group, randomized controlled trial design with the assessor blinded to the group allocation of participants. Ninety-eight (49 per arm) progressive MS patients (EDSS scale 6-7) will be randomly assigned to receive twelve 2-h training sessions over a 4-week period (three sessions/week) of either: (1) RAGT intervention on a robotic-driven gait orthosis (Lokomat, Hocoma, Switzerland). The training parameters (torque of the knee and hip drives, treadmill speed, body weight support) are set during the first session and progressively adjusted during training progression or (2) individual conventional physiotherapy focusing on over-ground walking training performed with the habitual walking device. The same assessors will perform outcome measurements at four time points: baseline (before the first intervention session); intermediate (after six training sessions); end of treatment (after the completion of 12 sessions); and follow-up (after 3 months from the end of the training program). The primary outcome is gait speed, assessed by the Timed 25-Foot Walk Test. We will also assess walking endurance, balance, depression, fatigue and QoL as well as instrumental laboratory markers (muscle metabolism, cerebral venous hemodynamics, cortical activation) and circulating laboratory markers (rare circulating cell populations pro and anti-inflammatory cytokines/chemokines, growth factors, neurotrophic factors, coagulation factors, other plasma proteins suggested by transcriptomic analysis and metabolic parameters).

Discussion: The RAGT training is expected to improve mobility compared to the active control intervention in progressive MS. Unique to this study is the analysis of various potential markers of plasticity in relation with clinical outcomes.

Trial registration: ClinicalTrials.gov, identifier: NCT02421731 . Registered on 19 January 2015 (retrospectively registered).

Keywords: Biological markers; Mobility; Motor recovery; Plasticity; Progressive multiple sclerosis; Rehabilitation; Robot-assisted gait training.

Figures

Fig. 1
Fig. 1
Design of the RAGTIME Study. EDSS expanded disability status scale, RAGT robot-assisted gait training

References

    1. Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL. Genetics and pathogenesis of multiple sclerosis. Semin Immunol. 2009;21(6):328–33. doi: 10.1016/j.smim.2009.08.003.
    1. Carr HJ, Shepherd RB. Neurological rehabilitation. Optimizing motor performance. Oxford: Butterworth Heinemann; 1998.
    1. Thoumie P, Lamotte D, Cantalloube S, Faucher M, Amarenco G. Motor determinants of gait in 100 ambulatory patients with multiple sclerosis. Mult Scler. 2005;11(4):485–91. doi: 10.1191/1352458505ms1176oa.
    1. Benedetti MG, Gasparroni V, Stecchi S, Zilioli R, Straudi S, Piperno R. Treadmill exercise in early multiple sclerosis: a case series study. Eur J Phys Rehabil Med. 2009;45(1):53–9.
    1. Swingler RJ, Compston D. The morbidity of multiple sclerosis. Q J Med. 1992;83(300):325–37.
    1. Lord SE, Wade DT, Halligan PW. A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin Rehabil. 1998;12(6):477–86. doi: 10.1191/026921598675863454.
    1. Cattaneo D, De Nuzzo C, Fascia T, Macalli M, Pisoni I, Cardini R. Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil. 2002;83(6):864–7. doi: 10.1053/apmr.2002.32825.
    1. Thompson A. Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis. Mult Scler. 2004;10(Suppl 1):S2–7. doi: 10.1177/135245850401000102.
    1. Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;1:CD003980.
    1. Wier LM, Hatcher MS, Triche EW, Lo AC. Effect of robot-assisted versus conventional body-weight-supported treadmill training on quality of life for people with multiple sclerosis. J Rehabil Res Dev. 2011;48(4):483–92. doi: 10.1682/JRRD.2010.03.0035.
    1. Tramonti F, Fanciullacci C, Giunti G, Rossi B, Chisari C. Functional status and quality of life of stroke survivors undergoing rehabilitation programmes in a hospital setting. NeuroRehabilitation. 2014;35(1):1–7.
    1. Solari A, Filippini G, Gasco P, Colla L, Salmaggi A, La Mantia L, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology. 1999;52(1):57–62. doi: 10.1212/WNL.52.1.57.
    1. Wiles CM, Newcombe RG, Fuller KJ, Shaw S, Furnival-Doran J, Pickersgill TP, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70(2):174–9. doi: 10.1136/jnnp.70.2.174.
    1. Gutierrez GM, Chow JW, Tillman MD, McCoy SC, Castellano V, White LJ. Resistance training improves gait kinematics in persons with multiple sclerosis. Arch Phys Med Rehabil. 2005;86(9):1824–9. doi: 10.1016/j.apmr.2005.04.008.
    1. Newman MA, Dawes H, van den Berg M, Wade DT, Burridge J, Izadi H. Can aerobic treadmill training reduce the effort of walking and fatigue in people with multiple sclerosis: a pilot study. Mult Scler. 2007;13(1):113–9. doi: 10.1177/1352458506071169.
    1. Patti F, Ciancio MR, Cacopardo M, Reggio E, Fiorilla T, Palermo F, et al. Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients—a randomised controlled trial. J Neurol. 2003;250(7):861–6. doi: 10.1007/s00415-003-1097-x.
    1. Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler. 2008;14(1):35–53. doi: 10.1177/1352458507079445.
    1. Lo AC, Triche EW. Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. Neurorehabil Neural Repair. 2008;22(6):661–71. doi: 10.1177/1545968308318473.
    1. Beer S, Aschbacher B, Manoglou D, Gamper E, Kool J, Kesselring J. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. Mult Scler. 2008;14(2):231–6. doi: 10.1177/1352458507082358.
    1. Giesser B, Beres-Jones J, Budovitch A, Herlihy E, Harkema S. Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler. 2007;13(2):224–31. doi: 10.1177/1352458506070663.
    1. Pilutti LA, Lelli DA, Paulseth JE, Crome M, Jiang S, Rathbone MP, et al. Effects of 12 weeks of supported treadmill training on functional ability and quality of life in progressive multiple sclerosis: a pilot study. Arch Phys Med Rehabil. 2011;92(1):31–6. doi: 10.1016/j.apmr.2010.08.027.
    1. Vaney C, Gattlen B, Lugon-Moulin V, Meichtry A, Hausammann R, Foinant D, et al. Robotic-assisted step training (lokomat) not superior to equal intensity of over-ground rehabilitation in patients with multiple sclerosis. Neurorehabil Neural Repair. 2012;26(3):212–21. doi: 10.1177/1545968311425923.
    1. Schwartz I, Sajin A, Moreh E, Fisher I, Neeb M, Forest A, et al. Robot-assisted gait training in multiple sclerosis patients: a randomized trial. Mult Scler. 2012;18(6):881–90. doi: 10.1177/1352458511431075.
    1. Straudi S, Benedetti MG, Venturini E, Manca M, Foti C, Basaglia N. Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial. NeuroRehabilitation. 2013;33(4):555–63.
    1. Gandolfi M, Geroin C, Picelli A, Munari D, Waldner A, Tamburin S, et al. Robot-assisted vs. sensory integration training in treating gait and balance dysfunctions in patients with multiple sclerosis: a randomized controlled trial. Front Hum Neurosci. 2014;8:318. doi: 10.3389/fnhum.2014.00318.
    1. Straudi S, Fanciullacci C, Martinuzzi C, Pavarelli C, Rossi B, Chisari C, et al. The effects of robot-assisted gait training in progressive multiple sclerosis: a randomized controlled trial. Mult Scler. 2016;22(3):373–84. doi: 10.1177/1352458515620933.
    1. Ruiz J, Labas MP, Triche EW, Lo AC. Combination of robot-assisted and conventional body-weight-supported treadmill training improves gait in persons with multiple sclerosis: a pilot study. J Neurol Phys Ther. 2013;37(4):187–93. doi: 10.1097/NPT.0000000000000018.
    1. Swinnen E, Beckwée D, Pinte D, Meeusen R, Baeyens JP, Kerckhofs E. Treadmill training in multiple sclerosis: can body weight support or robot assistance provide added value? A systematic review. Mult Scler Int. 2012;2012:240274.
    1. Tomassini V, Matthews PM, Thompson AJ, Fuglø D, Geurts JJ, Johansen-Berg H, et al. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 2012;8:635–46. doi: 10.1038/nrneurol.2012.179.
    1. Mezzapesa DM, Rocca MA, Rodegher M, Comi G, Filippi M. Functional cortical changes of the sensorimotor network are associated with clinical recovery in multiple sclerosis. Hum Brain Mapp. 2008;29(5):562–73. doi: 10.1002/hbm.20418.
    1. Pantano P, Mainero C, Lenzi D, Caramia F, Iannetti GD, Piattella MC, et al. A longitudinal fMRI study on motor activity in patients with multiple sclerosis. Brain. 2005;128(Pt 9):2146–53. doi: 10.1093/brain/awh549.
    1. Reddy H, Narayanan S, Matthews PM, Hoge RD, Pike GB, Duquette P, et al. Relating axonal injury to functional recovery in MS. Neurology. 2000;54(1):236–9. doi: 10.1212/WNL.54.1.236.
    1. Cifelli A, Matthews PM. Cerebral plasticity in multiple sclerosis: insights from fMRI. Mult Scler. 2002;8(3):193–9. doi: 10.1191/1352458502ms820oa.
    1. Schoonheim MM, Geurts JJ, Barkhof F. The limits of functional reorganization in multiple sclerosis. Neurology. 2010;74(16):1246–7. doi: 10.1212/WNL.0b013e3181db9957.
    1. Ksiazek-Winiarek DJ, Szpakowski P, Glabinski A. Neural plasticity in multiple sclerosis: the functional and molecular background. Neural Plast. 2015. doi:10.1155/2015/307175.
    1. Reddy H, Narayanan S, Woolrich M, Mitsumori T, Lapierre Y, Arnold DL, et al. Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. Brain. 2002;125:2646–57. doi: 10.1093/brain/awf283.
    1. Rocca MA, Colombo B, Falini A, Ghezzi A, Martinelli V, Scotti G, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 2005;4:618–26. doi: 10.1016/S1474-4422(05)70171-X.
    1. Jimenez JJ, Yang R, Nathoo N, Varshney VP, Golestani AM, Goodyear BG, et al. Detection of reduced interhemispheric cortical communication during task execution in multiple sclerosis patients using functional near-infrared spectroscopy. J Biomed Opt. 2014. doi:10.1117/1.JBO.19.7.076008.
    1. Cowansage KK, LeDoux JE, Monfils MH. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol. 2010;3(1):12–29. doi: 10.2174/1874467211003010012.
    1. Tongiorgi E, Sartori A, Baj G, Bratina A, Di Cola F, Zorzon M, et al. Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis. J Neurol Sci. 2012;320(1-2):161–5. doi: 10.1016/j.jns.2012.07.016.
    1. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(Pt 3):393–9. doi: 10.1093/brain/120.3.393.
    1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278–85. doi: 10.1056/NEJM199801293380502.
    1. Rottlaender A, Villwock H, Addicks K, Kuerten S. Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis. Immunology. 2011;133(3):370–8. doi: 10.1111/j.1365-2567.2011.03450.x.
    1. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol. 2007;178(1):39–48. doi: 10.4049/jimmunol.178.1.39.
    1. Frost EE, Nielsen JA, Le TQ, Armstrong RC. PDGF and FGF2 regulate oligodendrocyte progenitor responses to demyelination. J Neurobiol. 2003;54(3):457–72. doi: 10.1002/neu.10158.
    1. Harirchian MH, Tekieh AH, Modabbernia A, Aghamollaii V, Tafakhori A, Ghaffarpour M, et al. Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study. Eur J Neurol. 2012;19(2):241–7. doi: 10.1111/j.1468-1331.2011.03476.x.
    1. Campbell GR, Worrall JT, Mahad DJ. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult Scler. 2014;20(14):1806–13. doi: 10.1177/1352458514544537.
    1. Albanese M, Zagaglia S, Landi D, Boffa L, Nicoletti CG, Marciani MG, et al. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. J Neuroinflammation. 2016;13(1):36. doi: 10.1186/s12974-016-0502-1.
    1. Regenold WT, Phatak P, Makley MJ, Stone RD, Kling MA. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci. 2008;275(1-2):106–12. doi: 10.1016/j.jns.2008.07.032.
    1. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci. 2011;34(4):198–209. doi: 10.1016/j.tins.2011.01.005.
    1. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol. 2011;95(2):213–28. doi: 10.1016/j.pneurobio.2011.08.005.
    1. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. doi: 10.1002/ana.22366.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33(11):1444–52. doi: 10.1212/WNL.33.11.1444.
    1. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922–35. doi: 10.1111/j.1532-5415.1992.tb01992.x.
    1. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206–7. doi: 10.1093/ptj/67.2.206.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191–4. doi: 10.1016/S0140-6736(00)04337-3.
    1. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2(2):92–8.
    1. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(Pt5):871–82. doi: 10.1093/brain/122.5.871.
    1. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14(3):383–90. doi: 10.1177/1352458507082607.
    1. Berg K, Wood-Dauphinee S, Williams JI, Gayton D. Measuring balance in the elderly: Preliminary development of an instrument. Physiother Can. 1989;41:304–11. doi: 10.3138/ptc.41.6.304.
    1. Cattaneo D, Regola A, Meotti M. Validity of six balance disorders scales in persons with multiple sclerosis. Disabil Rehabil. 2006;28(12):789–95. doi: 10.1080/09638280500404289.
    1. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8. doi: 10.1111/j.1532-5415.1991.tb01616.x.
    1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3. doi: 10.1001/archneur.1989.00520460115022.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Sjonnesen K, Berzins S, Fiest KM, Bulloch AG M, Metz LM, Thombs BD, et al. Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. Postgrad Med. 2012;124(5):69–77. doi: 10.3810/pgm.2012.09.2595.
    1. Isaksson AK, Ahlström G, Gunnarsson LG. Quality of life and impairment in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(1):64–9. doi: 10.1136/jnnp.2003.029660.
    1. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124(Pt 5):962–73. doi: 10.1093/brain/124.5.962.
    1. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12) Neurology. 2003;60(1):31–6. doi: 10.1212/WNL.60.1.31.
    1. Zamboni P, Sisini F, Menegatti E, Taibi A, Malagoni AM, Morovic S, et al. An ultrasound model to calculate the brain blood outflow through collateral vessels: a pilot study. BMC Neurol. 2013;13:81. doi: 10.1186/1471-2377-13-81.
    1. Malagoni AM, Felisatti M, Lamberti N, Basaglia N, Manfredini R, Salvi F, et al. Muscle oxygen consumption by NIRS and mobility in multiple sclerosis patients. BMC Neurol. 2013;13:52. doi: 10.1186/1471-2377-13-52.
    1. Malagoni AM, Felisatti M, Mandini S, Mascoli F, Manfredini R, Basaglia N, et al. Resting muscle oxygen consumption by near-infrared spectroscopy in peripheral arterial disease: a parameter to be considered in a clinical setting? Angiology. 2010;61(6):530–6. doi: 10.1177/0003319710362975.
    1. Miyai I, Yagura H, Hatakenaka M, Oda I, Konishi I, Kubota K. Longitudinal optical imaging study for locomotor recovery after stroke. Stroke. 2003;34(12):2866–70. doi: 10.1161/01.STR.0000100166.81077.8A.
    1. Winzler C, Fantinato M, Giordan M, Calore E, Basso G, Messina C. CD4(+) T regulatory cells are more resistant to DNA damage compared to CD4(+) T effector cells as revealed by flow cytometric analysis. Cytometry A. 2011;79(11):903–11. doi: 10.1002/cyto.a.21132.
    1. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007;2(4):805–10. doi: 10.1038/nprot.2007.111.
    1. Tisato V, Zamboni P, Menegatti E, Gianesini S, Volpi I, Zauli G, et al. Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. Cytokine. 2013;63(2):92–6. doi: 10.1016/j.cyto.2013.04.018.
    1. Kishimoto T, Matsuoka T, Imamura S, Mizuno K. A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Clin Chim Acta. 2003;333(1):59–67. doi: 10.1016/S0009-8981(03)00165-7.
    1. Gloster JA, Harris P. Observations on an enzymic method for the estimation of pyruvate in blood. Clin Chim Acta. 1962;7:206–11. doi: 10.1016/0009-8981(62)90011-6.
    1. Tornese G, Iafusco D, Monasta L, Agnoletto C, Tisato V, Ventura A, et al. The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. Acta Diabetol. 2014;51(2):239–46. doi: 10.1007/s00592-013-0507-5.
    1. Martinelli N, Girelli D, Baroni M, Guarini P, Sandri M, Lunghi B, et al. Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study. J Thromb Haemost. 2016;14(4):655–66. doi: 10.1111/jth.13274.
    1. Marchetti G, Girelli D, Zerbinati C, Lunghi B, Friso S, Meneghetti S, et al. An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis. Thromb Haemost. 2015;113(3):655–63. doi: 10.1160/TH14-05-0466.
    1. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27(3):502–22. doi: 10.1016/0003-2697(69)90064-5.
    1. Groenwold RH, Donders AR, Roes KC, Harrell FE, Jr, Moons KG. Dealing with missing outcome data in randomized trials and observational studies. Am J Epidemiol. 2012;175(3):210–7. doi: 10.1093/aje/kwr302.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere